Stifel Nicolaus analyst Dylan Van Haaften has maintained their bullish stance on SEMHF stock, giving a Buy rating on April 25.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Dylan Van Haaften’s rating is based on Siemens Healthineers AG’s strong performance in its Imaging segment, which significantly exceeded expectations. The company reported a notable revenue increase, driven by a favorable business mix and strategic cost management in Diagnostics, contributing to an overall positive financial outlook.
Additionally, the company’s ability to maintain a solid order intake in the Imaging segment, despite potential tariff impacts, demonstrates resilience and market competitiveness. The adjusted EBIT beat, primarily from the Imaging segment, further supports the Buy rating, as it indicates effective management and operational strength. These factors, combined with a stable dividend yield and improving net debt/EBITDA ratios, underpin the positive outlook for Siemens Healthineers AG.
In another report released on April 25, HSBC also upgraded the stock to a Buy with a €58.00 price target.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SEMHF in relation to earlier this year.